ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1588797
Effects of sodium/glucose cotransporter 2 inhibitors on the coagulation profile in patients with coronary-artery disease and type 2 diabetes mellitus: A retrospective cohort study
Provisionally accepted
Xiaoyue Qin
Guobin Song*- Shijiazhuang People’s Hospital, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Aims: Patients with coronary-artery disease (CAD) and type 2 diabetes mellitus (T2DM) are often in a hypercoagulable state and have an increased thrombosis risk. We aimed to evaluate the effects of sodium/glucose cotransporter 2 inhibitors (SGLT2is) on coagulation function and explore their potential role in regulating coagulation in these patients.Methods: We conducted a retrospective cohort study between June 2020 and June 2024 in patients with CAD and T2DM. Eligible patients were assigned to either the SGLT2i or non-SGLT2i group.Clinical information, laboratory tests, and echocardiographic (EKG) examination results were retrieved. We performed inter-and intragroup comparisons of coagulation function measurements before and after treatment, and also conducted regression analysis to assess the impact of treatment on coagulation function.Results: A total of 121 patients were included, with 49 and 72 in the SGLT2i and non-SGLT2i groups, respectively. After 30 days of treatment, antithrombin III (AT-III) activity increased by 5.39% (P = 0.026) in the SGLT2i group, but slightly decreased in the non-SGLT2i group. SGLT2is also decreased D-dimer levels by 95 mg/L (group P = 0.051, group:time P = 0.075). Further regression analysis showed a significant interaction between group and time for AT-III and D-dimer (P = 0.026 and P = 0.039). Additionally, prothrombin time (PT) showed a slight increase after SGLT2i treatment.2 Conclusion: SGLT2is could affect coagulation function by prolonging coagulation time and increasing anticoagulatory activity in patients with T2DM and CAD. These drugs could be used to ameliorate hypercoagulable states and reduce thrombosis risk in these patients.
Keywords: Sodium/Glucose Cotransporter 2 inhibitors, Coronary-artery disease, type 2 diabetes mellitus, Coagulation profile, Activated partial thromboplastin time
Received: 06 Mar 2025; Accepted: 21 Apr 2025.
Copyright: © 2025 Qin and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guobin Song, Shijiazhuang People’s Hospital, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.